Back to Journals » OncoTargets and Therapy » Volume 6

Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis

Authors Cheng Q, Yi B, Wang A, Jiang X

Received 9 August 2013

Accepted for publication 21 September 2013

Published 18 November 2013 Volume 2013:6 Pages 1675—1684


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Qingbao Cheng,* Bin Yi,* Aihua Wang,* Xiaoqing Jiang

Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China

*These authors contributed equally to this work

Abstract: miRNAs (miRs) are short RNA molecules that are involved in the posttranscriptional regulation of mRNA. The roles of miRs in tumor pathogenesis have only recently become a focus of research. It is becoming increasingly clear that miRs are important regulators of apoptosis, proliferation, invasion, and metastasis in cancer cells during cancer genesis and progression, furthering our understanding of cancer. In the present review, we summarize and evaluate the recent advances in our understanding of the characteristics of miRs as well as their regulated functions in cancer stem cells (CSCs), the epithelial-mesenchymal transition (EMT), and the tumor microenvironment (TM), describing their roles in tumor pathogenesis and their possible use as new therapeutic targets and biomarkers.

Keywords: miRNA, cancer stem cell, epithelial-mesenchymal transition, tumor microenvironment

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.